Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Regeneus Ltd. ( (AU:CMB) ) is now available.
Cambium Bio has strengthened its funding position ahead of pivotal Phase 3 trials of its dry eye candidate Elate Ocular®, receiving a A$0.6 million R&D Tax Incentive refund under an approved Advance Overseas Finding that provides a 43.5% cash rebate on eligible R&D spending through FY2027. The company also secured a A$2.4 million strategic placement at a 20% premium from major shareholder Zheng Yang Biomedical Technology, which, subject to shareholder approval in March, will help fund the initiation of patient dosing in its CAMOMILE-2 and CAMOMILE-3 Phase 3 studies, while it advances manufacturing, clinical preparations and licensing discussions for Elate Ocular® in Europe and the Middle East to support its future commercialisation and broaden its international footprint.
The most recent analyst rating on (AU:CMB) stock is a Hold with a A$0.55 price target. To see the full list of analyst forecasts on Regeneus Ltd. stock, see the AU:CMB Stock Forecast page.
More about Regeneus Ltd.
Cambium Bio Limited is a clinical-stage regenerative medicine company developing innovative biologic therapies for ophthalmology and tissue repair, with a lead focus on treatments for dry eye disease. The company is advancing its flagship candidate Elate Ocular® through late-stage clinical development, targeting global markets including the United States, Europe and the Middle East for its ophthalmic biologics portfolio.
Average Trading Volume: 4,122
Technical Sentiment Signal: Hold
Current Market Cap: A$12.86M
See more insights into CMB stock on TipRanks’ Stock Analysis page.